

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION OF THE BOARD COMMITTEES**

### **RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Ascletis Pharma Inc. (the “**Company**”) announces that it received a letter of resignation from Dr. Ru Rong JI (“**Dr. Ji**”) on June 30, 2020 resigning from his positions as an independent non-executive Director and a member of each of the remuneration committee and the nomination committee of the Board, with effect from June 30, 2020, to allow him to devote more time to his other personal commitments.

“Over the past two years, the Company has grown into multiple therapeutic areas covering NASH, HBV, HCV and HIV, especially with leading NASH and HBV pipeline.” Dr. Ji said, “I truly enjoy working with the management team and other board members. Due to the increasing responsibilities and workload as a professor and co-director of Center for Translational Pain Medicine at Duke University, Durham, North Carolina, I truly regret that I need to resign from the Board to focus on my research at Duke. I believe that the Company will have a bright future.”

Dr. Ji has confirmed that he has no disagreement with the Board and there are no other matters with respect to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to thank Dr. Ji for his efforts and valuable contributions to the Company during his tenure of office.

## CHANGES IN COMPOSITION OF THE BOARD COMMITTEES

The Board further announces that Mrs. Judy Hejingdao WU will replace Dr. Ji as a member of the remuneration committee of the Board, and Dr. Yizhen WEI will replace Dr. Ji as a member of the nomination committee of the Board, with effect from June 30, 2020.

By order of the Board  
**Ascletris Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People's Republic of China  
June 30, 2020

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*